Laboratory Diagnosis and Therapeutic Monitoring of Patients with Bleeding Disorders: Avoiding Pitfalls...Enhancing Care

Date: Tuesday, August 1, 2017
Registration & Reception: 6:00 - 6:30 pm
Presentation: 6:30 - 8:00 pm
Location: Marriott Marquis San Diego Marina
                       San Diego, California
                       Marina Ballroom, Salon D
                       South Tower, Level 3

Target Audience
This activity has been designed to meet the educational needs of diagnostic laboratory professionals including pathologists, pathology residents, laboratory directors, laboratory managers and administrators, medical technicians and technologists, hospital administrators, their support staff, and other clinicians who are interested in the management of patients with hemophilia and von Willebrand disease (VWD).

Statement of Need/Program Overview
Hematology laboratories are vital for the diagnosis of many benign blood disorders and for monitoring some therapies, including those used to control bleeding in patients with congenital factor deficiencies or dysfunctional proteins, such as hemophilia and VWD. Improvements in hematology laboratory diagnostics are highly dependent on new discoveries in assay development and replacement therapies for such hematologic disorders; the transition of new knowledge into assays for clinical testing purposes; and research that assesses, compares, and optimizes diagnostic practices.

Educational Objectives
After completing this activity, the participant should be better able to:
  • Evaluate current issues, challenges, and problems related to the laboratory assessment of non-severe hemophilia A and B
  • Describe the major differences between the one-stage and chromogenic factor activity assays
  • Discuss the advantages and disadvantages of the chromogenic factor activity assay in non-severe hemophilia A
  • Effectively monitor new recombinant factor replacement therapies
  • Describe the issues in accurate factor activity recovery following treatment with new recombinant factor replacement therapies depending on the activated partial thromboplastin time reagent used.
  • Evaluate current issues, challenges, and problems related to the laboratory assessment of VWD

Faculty Chair

Dorothy M. Adcock
Dorothy M. Adcock, MD
Medical Director, Colorado Coagulation
Laboratory Corporation of America® Holdings
Englewood, Colorado

Faculty Presenters

Stefan Tiefenbacher
Stefan Tiefenbacher, PhD
Technical Director, Vice President Colorado Coagulation
Laboratory Corporation of America® Holdings
Englewood, Colorado

Kenneth D. Friedman
Kenneth D. Friedman, MD
Medical Director, Hemostasis Reference Laboratory
Professor of Internal Medicine
BloodCenter of Wisconsin and Medical College of Wisconsin
Milwaukee, Wisconsin

Program Agenda

6:30 - 6:35 pm

Introduction and Symposium Overview

Dorothy Adcock, MD

6:35 — 7:00 pm

Challenges in the Laboratory Diagnosis of Non-Severe Hemophilia A and B

Dorothy Adcock, MD

7:00 — 7:25 pm

New Modified FVIII and IX Products and Laboratory Issues Associated with Their Measurement

Stefan Tiefenbacher, PhD

7:25 — 7:50 pm

Challenges of Laboratory Diagnosis of von Willebrand Disease

Kenneth Friedman, MD

7:50 — 8:00 pm

Q&A

Panel

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Foundation and Educational Concepts in Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

ACCENT® Credit Hours
The American Association for Clinical Chemistry (AACC) designates this activity for a maximum of 1.5 ACCENT® credit hours towards the AACC Clinical Chemist’s Recognition Award. AACC is an approved provider of continuing education (CE) for clinical laboratory scientists licensed in states that require documentation of CE, including California, Florida, Louisiana, Montana, Nevada, North Dakota, Rhode Island, Tennessee, and West Virginia. ACCENT® credit is also recognized by several organizations: AAB, ABCC, ACS, AMT, ASCLS, ASCP, ASM, CAP, IFCC, and NRCC.

Fee Information
There is no registration fee for attending this symposium; however, seating is limited. Preregistration does not guarantee seating. We do recommend arriving at the symposium location early.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Dorothy M. Adcock, MD
Consulting Fees: Novo Nordisk, Baxalta, Bayer
Kenneth Friedman, MD
Salary: BloodCenter of Wisconsin Consulting Fees: Bayer and CSL Behring, Genentech, Shire Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Alexion
Stefan Tiefenbacher, PhD
Consulting Fees: Novo Nordisk
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager Reported Financial Relationship

PIM Clinical Reviewers: Trace Hutchison, PharmD; Samantha Mattiucci, PharmD CHCP; Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP

Have no real or apparent conflicts of interest to report.
ECM: Patrick J. Crowley, MBA, Partner/CFO; Helen Morfit, Program Manager; Larry Rosenberg, PhD, Medical Writer
Have no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Commercial Support
This educational activity is supported by an independent medical educational grant from Shire Pharmaceuticals, Inc.


Click the “Continue Registration” button to indicate you have reviewed the CME/CE information for this activity.
Continue Registration